Abstract:Inspired by the multivalent effect of surface‐displayed ligands on target association, an assembly‐glued strategy allows for development of supramolecular covalent inhibitors with the display‐induced proximity between noncovalent ligands and warheads. This concept is exemplified with a hypoxia‐activated supramolecular covalent inhibitor undergoing covalent conjugation with target protein EGFR for cancer therapy. Targeted covalent inhibitors are promising for drug discovery and challenged by the strict structural features for target proteins to sustain proximity‐induced conjugations. Herein, an assembly‐glued strategy is reported to create surface‐displayed supramolecular covalent inhibitors that leverage the display‐induced proximity between noncovalent ligands and warheads. The ligand and warhead are obtained via attaching an epidermal growth factor receptor (EGFR)‐binding segment or nitroreductase (NTR)‐activated moiety to bola‐amphiphilic peptides, respectively. Co‐assembling the ligand and warhead with a filler peptide glues them and forms the surface‐displayed covalent inhibitor. While the ligand associates with EGFR, the warhead undergoes NTR‐induced cysteine conjugation facilitated by the ligand‐EGFR association. In vitro studies show the reliable hypoxia‐activated inhibition of EGFR phosphorylation and enhanced cytotoxicity of the covalent inhibitor under hypoxic condition. In addition, this strategy also allows for creating covalent inhibitors targeting proteins without small molecular covalent drugs, due to the display‐induced proximity between ligands and warheads. In vivo results illustrate the prolonged retention of the covalent inhibitor and its efficacy in inhibiting tumor growth. These findings demonstrate that simultaneous surface display of ligands and warheads via assembly adhesives allows for implementation of covalent inhibition functions, thus providing a new strategy for developing covalent inhibitors in the future.

Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action

Covalent Inhibition in Drug Discovery

Recent applications of covalent chemistries in protein-protein interaction inhibitors

Covalent Binding Design Strategy: A Prospective Method for Discovery of Potent Targeted Anticancer Agents.

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond

Computational Mechanistic Insights into Reversible and Irreversible Covalent Inhibitors Targeting SARS-CoV-2 Mpro

Covalent Inhibitors: To Infinity and Beyond

CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors

Assembly‐Glued Ligands and Warheads for Hypoxia‐Activatable Supramolecular Covalent Inhibitors

Applications of covalent chemistry in targeted protein degradation

Landscape of In Silico Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and Targets

Covalent inhibitors meet epigenetics: New opportunities

Advances in covalent drug discovery

Advanced technologies for screening and identifying covalent inhibitors

Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation

Contribution of Noncovalent Recognition and Reactivity to the Optimization of Covalent Inhibitors: A Case Study on KRas G12C